Oncomine Companion Diagnostic News

1/24/2023

Thermo Fisher Scientific Partners with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso

9/27/2022

Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations/Fusions in Thyroid Cancers

8/12/2022

FDA Approves First NGS-Based Companion Diagnostic to Aid in Selecting Non-Small Cell Lung Cancer Patients with HER2 (ERBB2) Activating Mutations (SNVs & Exon 20 Insertions) for Treatment with ENHERTU

2/21/2022

Japan MHLW approved Oncomine Dx Target Test as a companion diagnostics for Eli Lilly’s RET-inhibitor in RET fusion positive thyroid cancer and RET mutation positive medullary thyroid cancer.

12/9/2021

FDA Approves NGS-Based Companion Diagnostic for EGFR Exon20 Insertion Mutant Non-Small Cell Lung Cancer Tumor Tissue

9/15/2021

FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's Targeted Therapy for NSCLC Patients with EGFR Exon20 Insertion Mutations.

9/10/2021

Oncomine Dx Target Test Receives MHLW Approval as a Companion Diagnostic for Eli Lilly's RET-Inhibitor in Non-Small Cell Lung Cancer in Japan

9/10/2021

FDA Approves NGS-Based Companion Diagnostic for Previously Treated IDH1-Mutated Cholangiocarcinoma

9/1/2021

Thermo Fisher Scientific and AstraZeneca to Co-Develop NGS-based Companion Diagnostics. Multiyear, global strategic collaboration to co-develop NGS-based companion diagnostics to support the AstraZeneca portfolio.

9/8/2020

FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer

8/17/2020

Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Hengrui Therapeutics, Inc.

7/8/2020

Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Chugai Pharmaceutical

6/23/2020

Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer

6/15/2020

FDA Grants Breakthrough Device Designation to Thermo Fisher Scientific's Oncomine Precision Assay to Identify IDH1 and IDH2 Mutations in Low-Grade Glioma Patients

3/12/2020

Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer

9/9/2019

Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor

10/17/2018

Thermo Fisher Scientific CE Marks Oncomine Dx Target Test

10/31/2017

Thermo Fisher Scientific Signs Oncology Companion Diagnostic Development Agreement with Blueprint Medicines

6/22/2017

FDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer Therapies

11/18/2015

Thermo Fisher Scientific Signs Development Agreement for Next-Generation Sequencing-Based Companion Diagnostic

 

Are you a healthcare professional?

あなたは医療関係者ですか?



We've detected your location to be Japan.

Sorry, this page is not available in your area.